Key DMD pipeline products remain on track to reach critical value inflection points in 2020 including conditional EU approval of Puldysa and pivotal “VISION-DMD” trial results of vamorolone. Both will be transformational for Santhera with the potential of a substantial re-rating. Santhera needs additional funds to finance its growth plans.

Key catalysts:

  1. CHMP opinion Puldysa in DMD (mid 2020)
  2. Vamorolone “VISION-DMD” pivotal trial results (Q4 2020)
  3. Puldysa EU launch (Q4 2020)

Go to Santhera valuation report